IONETIX and AlfaRim announced a strategic collaboration to commercialize cyclotron-produced actinium-225, a key isotope enabling next-generation targeted alpha therapies (TATs). 

This collaboration will accelerate the near-term scale-up of actinium-225 production to achieve a sustainable supply at commercial scale.

Actinium-225 (Ac-225)  is a powerful alpha-emitting radioisotope used to selectively destroy cancer cells while sparing healthy tissue. Ac-225-based treatments are currently being investigated in numerous clinical trials. However, the global supply of Ac- 225 remains severely limited due to methodologically low production volumes, limited processing capacity, and rapidly increasing demand. To address these bottlenecks, AlfaRim and IONETIX are combining their complementary resources to expand production and enable broader clinical access to Ac-225-based cancer therapies.

Hanno Mak , Chief Executive Officer of AlfaRim , stated: "We are pleased to be part of this strategic collaboration with IONETIX. This collaboration represents a significant step forward in our mission to enable alpha therapies. These joint efforts pave the way for a reliable and sustainable commercial supply of Ac-225 at scale." 

"We are pleased to partner with AlfaRim to provide these urgently needed radioisotopes to patients everywhere. A reliable commercial supply will be critical to ensuring patients receive the benefits of these treatments," added Kevin Cameron , Chief Executive Officer of IONETIX .